Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
The Journal of Molecular Diagnostics : JMD
|
February 27, 2026
Different States of Lung Allograft Injury Assessed by Plasma Donor-derived and Total Cell-free DNA
Alan Betensley, Katherine Vandervest, David J Ross, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Janeta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 20, 2008
Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues
Andrés S Hernández, Stephen G Swartz, Dorothy Slusarchyk, et al.
Journal of Medicinal Chemistry
|
April 13, 2001
A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors
J A Robl, R Sulsky, C Q Sun, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 18, 2007
Discovery, synthesis, and structure-activity studies of tetrazole based growth hormone secretagogues
Andrés S Hernández, Peter T W Cheng, Christa M Musial, et al.
Science Advances
|
November 26, 2025
Large-amplitude variability driven by giant dust storms on a planetary-mass companion
Xianyu Tan, Xi Zhang, Mark S Marley, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 13, 2007
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators
Lawrence G Hamann, Mark C Manfredi, Chongqing Sun, et al.
Journal of Medicinal Chemistry
|
March 16, 2022
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads
Mingzong Li, Zenon Konteatis, Nelamangala Nagaraja, et al.
Journal of Medicinal Chemistry
|
April 8, 2021
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion
Zenon Konteatis, Jeremy Travins, Stefan Gross, et al.
Journal of Medicinal Chemistry
|
July 22, 2005
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
David J Augeri, Jeffrey A Robl, David A Betebenner, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
The Journal of Molecular Diagnostics : JMD
|
February 27, 2026
Different States of Lung Allograft Injury Assessed by Plasma Donor-derived and Total Cell-free DNA
Alan Betensley, Katherine Vandervest, David J Ross, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Janeta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 20, 2008
Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues
Andrés S Hernández, Stephen G Swartz, Dorothy Slusarchyk, et al.
Journal of Medicinal Chemistry
|
April 13, 2001
A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors
J A Robl, R Sulsky, C Q Sun, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 18, 2007
Discovery, synthesis, and structure-activity studies of tetrazole based growth hormone secretagogues
Andrés S Hernández, Peter T W Cheng, Christa M Musial, et al.
Science Advances
|
November 26, 2025
Large-amplitude variability driven by giant dust storms on a planetary-mass companion
Xianyu Tan, Xi Zhang, Mark S Marley, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 13, 2007
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators
Lawrence G Hamann, Mark C Manfredi, Chongqing Sun, et al.
Journal of Medicinal Chemistry
|
March 16, 2022
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads
Mingzong Li, Zenon Konteatis, Nelamangala Nagaraja, et al.
Journal of Medicinal Chemistry
|
April 8, 2021
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion
Zenon Konteatis, Jeremy Travins, Stefan Gross, et al.
Journal of Medicinal Chemistry
|
July 22, 2005
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
David J Augeri, Jeffrey A Robl, David A Betebenner, et al.
Page
of 8